company background image
EGRX logo

Eagle Pharmaceuticals OTCPK:EGRX Stock Report

Last Price

US$0.55

Market Cap

US$7.8m

7D

-26.7%

1Y

-88.9%

Updated

20 Dec, 2024

Data

Company Financials

Eagle Pharmaceuticals, Inc.

OTCPK:EGRX Stock Report

Market Cap: US$7.8m

EGRX Stock Overview

A pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. More details

EGRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance1/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Eagle Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Eagle Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.55
52 Week HighUS$6.81
52 Week LowUS$0.0025
Beta0.67
1 Month Change-15.67%
3 Month Change-86.11%
1 Year Change-88.91%
3 Year Change-98.99%
5 Year Change-99.08%
Change since IPO-95.71%

Recent News & Updates

Recent updates

Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Sep 21
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Jul 13
Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

Jun 21
Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Oct 12

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Sep 27

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Aug 18

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Aug 15
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Aug 09

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Jul 06
These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Apr 29
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Shareholder Returns

EGRXUS BiotechsUS Market
7D-26.7%-5.6%-3.5%
1Y-88.9%-1.5%22.1%

Return vs Industry: EGRX underperformed the US Biotechs industry which returned -1.5% over the past year.

Return vs Market: EGRX underperformed the US Market which returned 22.1% over the past year.

Price Volatility

Is EGRX's price volatile compared to industry and market?
EGRX volatility
EGRX Average Weekly Movement51.3%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: EGRX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: EGRX's weekly volatility has increased from 28% to 51% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007134Mike Graveswww.eagleus.com

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.

Eagle Pharmaceuticals, Inc. Fundamentals Summary

How do Eagle Pharmaceuticals's earnings and revenue compare to its market cap?
EGRX fundamental statistics
Market capUS$7.81m
Earnings (TTM)US$11.95m
Revenue (TTM)US$257.55m

0.6x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EGRX income statement (TTM)
RevenueUS$257.55m
Cost of RevenueUS$77.68m
Gross ProfitUS$179.88m
Other ExpensesUS$167.93m
EarningsUS$11.95m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.92
Gross Margin69.84%
Net Profit Margin4.64%
Debt/Equity Ratio27.8%

How did EGRX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 01:55
End of Day Share Price 2024/12/20 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eagle Pharmaceuticals, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Louise ChenCantor Fitzgerald & Co.
Irina Rivkind KofflerMizuho Securities USA LLC
David AmsellemPiper Sandler Companies